placebo + linagliptin + background therapy

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Sep 30, 2016 โ†’ Jan 18, 2019

About placebo + linagliptin + background therapy

placebo + linagliptin + background therapy is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT02897349. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02897349Phase 3Completed